Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. The company is headquartered in Melbourne, Victoria. The firm develops and commercializes human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using proprietary and patented processes. The firm's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The firm's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol, Veterinary Applications, among others. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
AVEFF stock price ended at $0 on 星期五, after dropping 100.00%
On the latest trading day May 02, 2025, the stock price of AVEFF fell by 100.00%, dropping from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. On the latest trading day, the trading volume for AVEFF rose by 33.1K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 50.0K shares were traded, with a market value of approximately --.